Kura Oncology, Inc. KURA 深 滬
已收盤 02-06 16:00:00 美东时间
7.83
+0.430
+5.81%
華盛通- 最 高7.88
- 今 開7.54
- 成交量 153.92万股
- 最 低 7.54
- 昨 收 7.40
- 總市值 6.81亿
- 52周最高 12.49
- 市盈率 靜 --
- 換手率 1.77%
- 52周最低 5.41
- 委 比 -33.08%
- 總股本 8701.75万
- 歷史最高 43.00
- 量 比 1.13
- 振 幅 4.59%
- 歷史最低 2.50
- 每 手 1
- 風險率 1.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kura Oncology Tightens Governance with Amended Bylaws
The latest update is out from Kura Oncology ( ($KURA) ). On January 28, 2026, K...
01-30 07:04
Kura Oncology SVP Thomas James Doyle Disposes of Common Shares
Kura Oncology SVP Thomas James Doyle Disposes of Common Shares Thomas James Doyle, SVP, Finance & Accounting of Kura Oncology Inc., reported a disposal of common shares of Kura Oncology Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Tec
01-28 10:35
Kura Oncology Chief Medical Officer Mollie Leoni Reports Sale of Common Shares
Kura Oncology Chief Medical Officer Mollie Leoni Reports Sale of Common Shares Mollie Leoni, Chief Medical Officer of Kura Oncology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Tec
01-28 10:35
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology launched KOMZIFTI™ (ziftomenib), the first and only once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML. The drug generated $2.1 million in net product revenue from its commercial launch on November 21, 2025, through December 31, 2025. Kura plans to accelerate U.S. adoption of KOMZIFTI and grow net product revenue in 2026. The company is exploring ziftomenib in combinations and earlier lines of t...
01-11 22:00
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted 49,750 nonstatutory stock options to three new employees under its 2023 Inducement Option Plan on January 2, 2026. The options, priced at USD 10.34 per share (closing price on the grant date), vest over four years, with 25% vesting after the first year and the remaining shares vesting monthly over the next 36 months, contingent on continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4)._Kura Oncology foc...
01-05 12:30
Kura Oncology rises following Jim Cramer comments
A mention on the Dec. 19 episode of CNBC's "Mad Money" hosted by Jim Cramer of Kura Oncology (KURA) is sending shares of the biotech higher by 12% in Monday trading. Cramer said, "I have always felt t...
2025-12-23 01:01
Kyowa Kirin announces management changes
Kyowa Kirin (KYKOF) (KNBWY) appointed Abdul Mullick, Ph.D., as President and CEO effective March 2026. This follows a dual CEO/COO leadership model implemented in March 2025, where Mullick served as C...
2025-12-11 16:12
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Kura Oncology announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), triggering a $135 million milestone payment from Kyowa Kirin, which Kura expects to receive before year-end. KOMZIFTI received FDA approval on November 13, 2025. The drug is a once-daily, oral menin inhibitor for treating adults with relapsed or refractory *NPM1*-mutated acute myeloid leukemia. Kura, a biopharma company focused on precision oncology, developed KOMZI...
2025-12-02 13:02
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated AML, is now commercially available in the United States. It has been included in the NCCN Guidelines as a Category 2A recommended treatment. KOMZIFTI received full approval on November 13, 2025, supported by clinical trial data showing a 21.4% CR/CRh rate and a median response duration of 5 months. The drug is now available through special...
2025-11-25 22:16
